Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-directed phase 2 platform study after progression on first-line osimertinib in EGFR-mutant advanced non-small cell lung cancer
jRCT2080224686Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of osimertinib, savolitinib, gefitinib, necitumumab, durvalumab and 7 more in non-small cell lung cancer (NSCLC) (10 arms), sponsored by AstraZeneca. Started May 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224686.